Catalog No. |
TD-HY255016 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Humanized |
Isotype |
VH-VH |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
von Willebrand antigen II, von Willebrand factor, F8VWF, vWF, VWF |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P04275 |
Form |
Liquid |
Storage buffer |
20mM citric acid,6.2% sucrose,0.01% Tween80 |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
ALX-0081,PMP12A2h1-linkerAAA-PMP12A2h1,caplacizumab-yhdp,CAS:915810-67-2 |
Background |
Caplacizumab (ALX-0681) is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP). |
Note |
For research use only. Not for use in clinical or therapeutic applications. |